<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="366286">
  <stage>Registered</stage>
  <submitdate>8/05/2014</submitdate>
  <approvaldate>12/05/2014</approvaldate>
  <actrnumber>ACTRN12614000503628</actrnumber>
  <trial_identification>
    <studytitle>Differences in gut bacteria of patients with Clostridium difficile infection and patients with ulcerative colitis before and after faecal microbiota transplantation</studytitle>
    <scientifictitle>Single centre, proof-of-concept, exploratory, parallel, controlled study using high-throughput DNA sequencing techniques to compare differences in the gastrointestinal (GI) microflora of Clostridium difficile infection (CDI) and ulcerative colitis (UC) patients before and after faecal microbiota transplantation (FMT)</scientifictitle>
    <utrn>U1111-1156-5909</utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Clostridium difficile infection</healthcondition>
    <healthcondition>Ulcerative colitis</healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Inflammatory bowel disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Faecal microbiota transplantation (FMT).  2x 150mL FMTs will be administered on consecutive days.  The first FMT will be administered via a colonosocope and the second FMT will be administered via a rectal enema. </interventions>
    <comparator>None</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Donor microbiota implantation (defined as 50% similarity to the donor) as measured by high-throughput DNA sequencing of bacteria in stool </outcome>
      <timepoint>Day 3, Day 7, Day 14 and Day 28 after FMT </timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Relationship between donor microbiota implantation and clinical improvement as defined by a 3 point or greater improvement in Mayo score for ulcerative colitis patients or eradication of Clostridium difficile infection (CDI) and improvement in bowel frequency to 1-2 stools per day in CDI patients. </outcome>
      <timepoint>Day 30 after FMT</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>6 months or greater history of active moderate ulcerative colitis (Mayo score of 4-10) or diarrhoea (greater than 3 motions per day) in association with a confirmed diagnosis of Clostridium difficile infection (toxin positive).
Never had FMT treatment for any reason.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Females who are pregnant or lactating.
Unwilling to practice an effective method of contraception throughout the study period.
Unwilling to use a sodium picosulfate-based bowel preparation.
Severe anemia, leucopenia or granulocytopenia.
Detection of a gastrointestinal pathogen on stool analysis, with the exception of Clostridium difficile for the Clostridium difficile infection group only.
Participants with Crohns disease, indeterminate colitis or isolated proctitis &lt;5 cm.
Constipation-predominant ulcerative colitis with &lt;2 bowel motions/day.
Evidence or history of toxic megacolon.
Any other significant gastrointestinal conditions e.g. neoplasms, irritable bowel syndrome. 
Participants who have had a colectomy, bowel resection or other major gastrointestinal surgery.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>Allocation is not concealed.</concealment>
    <sequence />
    <masking />
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>24/04/2014</anticipatedstartdate>
    <actualstartdate>24/04/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>10</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>Centre for Digestive Diseases - Five Dock</hospital>
    <postcode>2046 - Five Dock</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Centre for Digestive Diseases</primarysponsorname>
    <primarysponsoraddress>Level 1, 229 Great North Rd
Five Dock NSW 2046</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Centre for Digestive Diseases</fundingname>
      <fundingaddress>Level 1, 229 Great North Rd
Five Dock NSW 2046</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>European Molecular Biology Laboratory</fundingname>
      <fundingaddress>Meyerhofstrasse 1
69117 Heidelberg</fundingaddress>
      <fundingcountry>Germany</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Faecal microbiota transplantation (FMT) is a highly successful treatment for Clostridium difficile infection (CDI) with success rates of over 90%.  Success rates of FMT treatment for ulcerative colitis (UC) are lower.  

The success of FMT in CDI treatment is believed to be in part due to the implantation of the full complement of bacteria from the FMT into the patient's bowel.  It is unclear if this implantation occurs with FMT in UC patients.  The lower success rate of FMT treatment for UC may be due to a failure of the bacteria from the FMT to implant in the bowel's of UC patients.  

This study will compare the composition and changes in the gut bacteria before and after FMT in patients with CDI and in patients with UC.  </summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Centre for Digestive Diseases Human Research Ethics Committee</ethicname>
      <ethicaddress>Level 1, 229 Great North Rd
Five Dock NSW 2046</ethicaddress>
      <ethicapprovaldate>20/03/2014</ethicapprovaldate>
      <hrec>CDD14/C02</hrec>
      <ethicsubmitdate>28/01/2014</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Thomas Borody</name>
      <address>Centre for Digestive Diseases
Level 1, 229 Great North Rd
Five Dock NSW 2046
</address>
      <phone>+61 2 9713 4011</phone>
      <fax />
      <email>cddresearch@cdd.com.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Enmoore Lin</name>
      <address>Centre for Digestive Diseases
Level 1, 229 Great North Rd
Five Dock NSW 2046</address>
      <phone>+61 2 9713 4011</phone>
      <fax />
      <email>enmoore.lin@cdd.com.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Enmoore Lin</name>
      <address>Centre for Digestive Diseases
Level 1, 229 Great North Rd
Five Dock NSW 2046</address>
      <phone>+61 2 9713 4011</phone>
      <fax />
      <email>enmoore.lin@cdd.com.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>